Md. Code Regs. 10.13.03.03

Current through Register Vol. 51, No. 25, December 13, 2024

Section 10.13.03.03 - General Provisions

A. When determined appropriate by the prescribing licensed health care provider, targeted patient populations may be co-prescribed an opioid overdose reversal drug, if the individual is at an elevated risk of experiencing an opioid overdose by virtue of belonging to one or more categories of the targeted patient population.

B. Responsibilities of the Prescribing licensed Health Care Provider.

(1) Risk Monitoring.

(a) It is suggested that the licensed health care provider routinely assess patients for their risk of being likely to experience or witness an opioid overdose.

(b) The prescriber may utilize additional sources of information for determining a patient's opioid overdose risk including, but not limited to:

(i) Checking the Maryland Prescription Drug Monitoring Program;

(ii) Reviewing medical records; and

(iii) Soliciting family input, if appropriate.

(2) Education. If a patient is assessed to be at risk of an opioid overdose, the prescriber may educate the patient about,, including but not limited to, the following areas:

(a) The risks of an opioid overdose; and

(b) How to identify and respond to an opioid overdose.

(3) Documentation. licensed health care providers should document education and clinical services related to the provision of an opioid overdose reversal drug in their patients' medical records in accordance with the standard of care.

Md. Code Regs. 10.13.03.03

Regulation .03 adopted effective 46:12 Md. R. 541, eff. 6/17/2019